Drug intelligence / Profile preview

jiaweimojie

Development stage: Unknown
Lead developer: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

Jiaweimojie is a Traditional Chinese Medicine (TCM) formulation developed by the Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. It is specifically designed for the treatment of primary dysmenorrhea associated with the qi stagnation and blood stasis syndrome. The drug is currently being evaluated in Phase III clinical trials in China to assess its efficacy and safety compared to placebo. Its therapeutic approach is based on TCM principles of invigorating blood flow and alleviating pain, likely utilizing key ingredients such as Myrrh (Mo Yao) and Dragon's Blood (Xue Jie).

Brand names: Jiawei Mojie TabletsJiawei Mojie pill
Other names: Jiaweimojie Tablets加味没竭片

Targets

Oxytocin receptor

Beyond the preview

Go deeper on jiaweimojie.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jiaweimojie.

Explore the full profile